LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy.

    Houssiau, Hélène / Pairet, Géraldine / Dano, Hélène / Seront, Emmanuel

    Current oncology (Toronto, Ont.)

    2023  Volume 30, Issue 12, Page(s) 10550–10555

    Abstract: Background: Bladder cancer is a highly aggressive cancer, and muscle invasive urothelial carcinoma (MIUC) requires aggressive strategy. Concomitant chemo-radiotherapy (CRT) appears as a therapeutic option that allows bladder sparing. No biomarker is ... ...

    Abstract Background: Bladder cancer is a highly aggressive cancer, and muscle invasive urothelial carcinoma (MIUC) requires aggressive strategy. Concomitant chemo-radiotherapy (CRT) appears as a therapeutic option that allows bladder sparing. No biomarker is currently available to optimally select patients for CRT.
    Methods: We retrospectively enrolled patients with MIUC who were treated in a curative setting with CRT. Based on c-MET expression in pre-treatment tumor tissue, patients were stratified into two groups: no expression of c-MET (group A) and expression of c-MET (group B). We evaluated the outcome of these patients based on c-MET expression.
    Results: After a median follow-up of 40 months, 13 patients were enrolled in this analysis, 8 in group A and 5 in group B. The disease recurrence was 25% in group A and 100% in group B. Compared to group A, patients from group B experienced more frequent and more rapid recurrence in terms of metastases; the 3-year metastatic recurrence rate was 13% and 100%, respectively. The c-MET expression was also associated with a higher rate of cancer-related deaths.
    Conclusions: In this retrospective analysis, c-MET expression was associated with worse disease-free survival and survival in patients treated radically with CRT.
    MeSH term(s) Humans ; Urinary Bladder Neoplasms/therapy ; Carcinoma, Transitional Cell/pathology ; Retrospective Studies ; Cystectomy ; Neoplasm Recurrence, Local ; Chemoradiotherapy ; Biomarkers
    Chemical Substances Biomarkers
    Language English
    Publishing date 2023-12-18
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 1236972-x
    ISSN 1718-7729 ; 1198-0052
    ISSN (online) 1718-7729
    ISSN 1198-0052
    DOI 10.3390/curroncol30120770
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4305: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Isolated peritoneal carcinomatosis in prostate cancer: from a successful hormonal management to a review of the literature.

    Delchambre, Emilie / Rysselinck, Stéphane / Pairet, Géraldine / Confente, Caterina / Seront, Emmanuel

    Future science OA

    2021  Volume 7, Issue 6, Page(s) FSO707

    Abstract: Metastases from prostate cancer involve mainly the bone compartment. However, visceral metastases are found in up to 49% of metastatic patients, occurring mainly in late stages of the disease, and are correlated with poor outcome. Peritoneal ... ...

    Abstract Metastases from prostate cancer involve mainly the bone compartment. However, visceral metastases are found in up to 49% of metastatic patients, occurring mainly in late stages of the disease, and are correlated with poor outcome. Peritoneal carcinomatosis is rarely described in literature, particularly when not associated with other distant metastatic lesions. We present the management of a patient with prostate cancer progressing on androgen deprivation therapy with description of omental involvement on
    Language English
    Publishing date 2021-04-30
    Publishing country England
    Document type Case Reports
    ISSN 2056-5623
    ISSN 2056-5623
    DOI 10.2144/fsoa-2021-0009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Isolated peritoneal carcinomatosis in prostate cancer

    Emilie Delchambre / Stéphane Rysselinck / Géraldine Pairet / Caterina Confente / Emmanuel Seront

    Future Science OA, Vol 7, Iss

    from a successful hormonal management to a review of the literature

    2021  Volume 6

    Abstract: Metastases from prostate cancer involve mainly the bone compartment. However, visceral metastases are found in up to 49% of metastatic patients, occurring mainly in late stages of the disease, and are correlated with poor outcome. Peritoneal ... ...

    Abstract Metastases from prostate cancer involve mainly the bone compartment. However, visceral metastases are found in up to 49% of metastatic patients, occurring mainly in late stages of the disease, and are correlated with poor outcome. Peritoneal carcinomatosis is rarely described in literature, particularly when not associated with other distant metastatic lesions. We present the management of a patient with prostate cancer progressing on androgen deprivation therapy with description of omental involvement on 68Ga PSMA-PET. There was no ascite or other distant lesion, reflecting thus a specific tropism of the cancer in this patient who had no history of prostate surgery. Abiraterone acetate resulted in a long-lasting complete response. We also present a review focusing on this entity.
    Keywords case report ; hormone therapy ; peritoneal carcinomatosis ; prostate cancer ; prostate-specific membrane antigen and PET ; Medicine ; R ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2021-07-01T00:00:00Z
    Publisher Future Science Ltd
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report.

    Yeo, Anne-Emmanuella / Hendrix, Aurore / Confente, Caterina / Christian, Nicolas / Mansvelt, Baudouin / Pairet, Géraldine / Seront, Emmanuel

    Frontiers in oncology

    2021  Volume 11, Page(s) 764758

    Abstract: Metastatic prostate cancer remains a challenge for clinicians. Metastases involve mainly the bone compartment and can manifest as oligometastatic disease. In this setting, the role of metastasis-directed therapies (MDT) including surgery and/or ... ...

    Abstract Metastatic prostate cancer remains a challenge for clinicians. Metastases involve mainly the bone compartment and can manifest as oligometastatic disease. In this setting, the role of metastasis-directed therapies (MDT) including surgery and/or stereotactic body radiotherapy is currently evaluated. Visceral metastases are less common and have very poor prognosis in mPC. Whether treating isolated visceral metastases such as liver metastases with MDT could increase the prognosis remains unknown. We report the management of a prostate cancer patient who progressed on androgen deprivation therapy with apparition of two liver metastases. We describe the feasibility of combining MDT with abiraterone acetate and prednisone in a patient with metastatic castration-resistant prostate cancer. MDT allowed the interruption of abiraterone acetate, preventing cumulative toxicity of this agent.
    Language English
    Publishing date 2021-11-17
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.764758
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Case Reports in Oncological Medicine Myoepithelioma: A New Rearrangement Involving the

    Pairet, Géraldine / Tilman, Gaëlle / Sciot, Rafaël / Schubert, Thomas / Perlepe, Vasiliki / Poirel, Hélène A / Galant, Christine

    Case reports in oncological medicine

    2018  Volume 2018, Page(s) 3512847

    Abstract: We report a case of multiple myoepithelioma with synchronous bone and soft tissue tumors, associated with a new genomic alteration of ... ...

    Abstract We report a case of multiple myoepithelioma with synchronous bone and soft tissue tumors, associated with a new genomic alteration of the
    Language English
    Publishing date 2018-02-27
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2629911-2
    ISSN 2090-6714 ; 2090-6706
    ISSN (online) 2090-6714
    ISSN 2090-6706
    DOI 10.1155/2018/3512847
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

    Mlecnik, Bernhard / Van den Eynde, Marc / Bindea, Gabriela / Church, Sarah E / Vasaturo, Angela / Fredriksen, Tessa / Lafontaine, Lucie / Haicheur, Nacilla / Marliot, Florence / Debetancourt, Daphné / Pairet, Géraldine / Jouret-Mourin, Anne / Gigot, Jean-Francois / Hubert, Catherine / Danse, Etienne / Dragean, Cristina / Carrasco, Javier / Humblet, Yves / Valge-Archer, Viia /
    Berger, Anne / Pagès, Franck / Machiels, Jean-Pascal / Galon, Jérôme

    Journal of the National Cancer Institute

    2017  Volume 110, Issue 1

    Abstract: Background: This study assesses how the metastatic immune landscape is impacting the response to treatment and the outcome of colorectal cancer (CRC) patients.: Methods: Complete curative resection of metastases (n = 441) was performed for two ... ...

    Abstract Background: This study assesses how the metastatic immune landscape is impacting the response to treatment and the outcome of colorectal cancer (CRC) patients.
    Methods: Complete curative resection of metastases (n = 441) was performed for two patient cohorts (n = 153). Immune densities were quantified in the center and invasive margin of all metastases. Immunoscore and T and B cell (TB) score were analyzed in relation to radiological and pathological responses and patient's disease-free (DFS) and overall survival (OS) using multivariable Cox proportional hazards models. All statistical tests were two-sided.
    Results: The spatial distribution of immune cells within metastases was nonuniform. Patients, as well as metastases of the same patient, had variable immune infiltrates and response to therapy. A beneficial response was statistically significantly associated with increased immune densities. Among all metastases, Immunoscore (I) and TB score evaluated in the least immune-infiltrated metastases were the strongest predictors for DFS and OS (five-year follow-up, Immunoscore: I 3-4: DFS rate = 27.9%, 95% CI = 15.2 to 51.3; vs I 0-1-2: DFS rate = 12.3%, 95% CI = 4.9 to 30.6; HR = 0.45, 95% CI = 0.28 to 0.70, P = .02; I 3-4: OS rate = 64.6%, 95% CI = 46.6 to 89.6; vs I 0-1-2: OS rate = 32.5%, 95% CI = 17.2 to 61.4; HR = 0.32, 95% CI = 0.15 to 0.66, P = .001, C-index = 65.9%; five-year follow-up, TB score: TB 3-4: DFS rate = 25.7%, 95% CI = 14.2 to 46.6; vs TB 0-1-2: DFS rate = 5.0%, 95% CI = 0.8 to 32.4; HR = 0.36, 95% CI = 0.22 to 0.57, P < .001; TB 3-4: OS rate = 63.7%, 95% CI = 46.4 to 87.5; vs TB 0-1-2: OS rate: 21.4%, 95% CI = 9.2 to 49.8; HR = 0.25, 95% CI = 0.12 to 0.51, P < .001, C-index = 67.8%). High TB score and Immunoscore patients had a median survival of 70.5 months, while low patients survived only 25.1 to 38.3 months. Nonresponding patients with high-immune infiltrates had prolonged DFS (HR = 0.28, 95% CI = 0.15 to 0.52, P = .001) and OS (HR = 0.25, 95% CI = 0.1 to 0.62, P = .001). The immune parameters remained the only statistically significant prognostic factor associated with DFS and OS in multivariable analysis (P < .001), while response to treatment was not.
    Conclusions: Response to treatment and prolonged survival of metastatic CRC patients were statistically significantly associated with high-immune densities quantified into the least immune-infiltrated metastasis.
    MeSH term(s) Aged ; Antigens, CD20/analysis ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; B-Lymphocytes/chemistry ; CD3 Complex/analysis ; CD8-Positive T-Lymphocytes ; Chemotherapy, Adjuvant ; Colorectal Neoplasms/immunology ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/therapy ; Disease-Free Survival ; Follow-Up Studies ; Forkhead Transcription Factors/analysis ; Hepatectomy ; Humans ; Leukocyte Common Antigens/analysis ; Liver Neoplasms/immunology ; Liver Neoplasms/secondary ; Liver Neoplasms/therapy ; Lung Neoplasms/immunology ; Lung Neoplasms/secondary ; Lung Neoplasms/therapy ; Lymphocyte Count ; Lymphocytes, Tumor-Infiltrating ; Metastasectomy ; Middle Aged ; Neoplasm Metastasis ; Pneumonectomy ; Preoperative Period ; Response Evaluation Criteria in Solid Tumors ; Survival Rate ; T-Lymphocytes/chemistry ; Tumor Microenvironment/immunology
    Chemical Substances Antigens, CD20 ; CD3 Complex ; FOXP3 protein, human ; Forkhead Transcription Factors ; Leukocyte Common Antigens (EC 3.1.3.48)
    Language English
    Publishing date 2017-09-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djx123
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.131: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top